Table 2.
Characteristics of included articles
| N = 77 (%) | |
|---|---|
| Name of journal | |
| - NEJM | 3 (4) |
| - The Lancet | 2 (3) |
| - JAMA | 13 (17) |
| - Annals of Internal Medicine | 9 (11) |
| - BMJ | 14 (18) |
| - PLoS Medicine | 8 (11) |
| - Circulation | 7 (9) |
| - European Heart Journal | 4 (5) |
| - Journal of the American College of Cardiology | 15 (19) |
| Location of corresponding authors | |
| - North America | 40 (52) |
| - Europe | 25 (32) |
| - Asia | 10 (13) |
| - North American and Europe | 1 (1) |
| - International | 1 (1) |
| Study design | |
| - Cohort study | 67 (87) |
| - Not clearly reported | 10 (13) |
| Treatment evaluated | |
| - Pharmacological treatment | 53 (69) |
| - Non-pharmacological treatment | 23 (30) |
| - Both | 1 (1) |
| Comparator | |
| - Active comparator | 49 (63) |
| - Usual care | 17 (22) |
| - No treatment | 11 (14) |
| Median sample size [min–max] | 24,000 [9100–80,000] |
| Data sourcea | |
| - Registry | 34 (44) |
| - Electronic health record | 17 (22) |
| - Health administration data | 14 (18) |
| - Health insurance claims data | 20 (26) |
| - Others | 11 (14) |
| Funding source | |
| - Not for profit | 43 (56) |
| - For profit | 7 (9) |
| - Both | 12 (16) |
| - No funding | 5 (6) |
| - Unclear | 10 (13) |
| Research transparency practices | |
| - Using a reporting guideline | 7 (9) |
| - Code and algorithm used to classify exposures provided in supplementary documents | 57 (74) |
| - Code and algorithm used to classify outcomes provided in supplementary documents | 60 (78) |
| - A statement to provide data upon request | 10 (13) |
aOne study might have more than one type of data sources